Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|September 23, 2010
PT V2 Promotions - Register - Content
Click here to register and receive these exclusive pdfs. After registering, you will be redirected to the page with the links to download.
Advertisement
Register with Psychiatric Times to receive these exclusive pdfs: "2010 Staff Salary Survey: Regional Data" and "What Should You Pay Staff?"
Sign up today and join our growing online community of healthcare professionals.
As a registered member you'll be able to:
–
Access exclusive members-only online content
–
Receive the latest in medical insights directly in your inbox
–
Download PDFs of Psychiatric Times articles
Click
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
4
Should Postpartum Psychosis Be Included in the DSM?
5